New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remodeling

New Insights into the Management of CKD in T2D: The Role of MRA Therapies

Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction

From Guidelines to Practice: Key Updates From 2021 HFSA

A Closer Look at Women, Atherosclerosis, and Lipids: What Is Different? 

Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes

A Clinical Guide to the Role of Iron in HF Pathophysiology

FIGARO-DKD and FIDELITY Analysis: Key Takeaways

Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal

RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option

Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness

Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case Study Approach

New Therapies Offer Improved Outcomes in HFrEF Management